|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Alexion's Soliris® (eculizumab) Receives Marketing Approval in Canada for Patients With Atypical HUS
3/6/2013 10:01:07 AM
ONTARIO, March 6, 2013 /CNW/ - Alexion Pharma Canada., a subsidiary of Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), today announced that Canada's national healthcare regulatory agency, Health Canada, has approved the use of Soliris® (eculizumab) for the treatment of patients with atypical hemolytic uremic syndrome (atypical HUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). Atypical HUS, or aHUS, is a life-threatening and chronic ultra-rare, genetic disease that progressively damages vital organs, leading to stroke, heart attack, kidney failure and death.1
|
|
|
|
|
|
|
|
|
|
|